Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Long-Term Investments (2016 - 2023)

Historic Long-Term Investments for AtriCure (ATRC) over the last 11 years, with Q2 2023 value amounting to $7.6 million.

  • AtriCure's Long-Term Investments fell 8818.26% to $7.6 million in Q2 2023 from the same period last year, while for Jun 2023 it was $7.6 million, marking a year-over-year decrease of 8818.26%. This contributed to the annual value of $51.5 million for FY2022, which is 5063.26% down from last year.
  • AtriCure's Long-Term Investments amounted to $7.6 million in Q2 2023, which was down 8818.26% from $25.6 million recorded in Q1 2023.
  • AtriCure's 5-year Long-Term Investments high stood at $105.1 million for Q3 2021, and its period low was $7.6 million during Q2 2023.
  • Moreover, its 5-year median value for Long-Term Investments was $23.0 million (2019), whereas its average is $40.7 million.
  • Per our database at Business Quant, AtriCure's Long-Term Investments surged by 67258.68% in 2022 and then tumbled by 8818.26% in 2023.
  • AtriCure's Long-Term Investments (Quarter) stood at $12.7 million in 2019, then increased by 11.86% to $14.2 million in 2020, then surged by 635.91% to $104.3 million in 2021, then tumbled by 50.63% to $51.5 million in 2022, then plummeted by 85.25% to $7.6 million in 2023.
  • Its Long-Term Investments was $7.6 million in Q2 2023, compared to $25.6 million in Q1 2023 and $51.5 million in Q4 2022.